LGVN Q1 2024 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$20M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$548,000+130.3% YoY

Gross Profit

$329,00060.0% margin

Operating Income

-$4M-746.4% margin

Net Income

-$4M-740.5% margin

EPS (Diluted)

$-1.61

QoQ Revenue Growth

+769.8%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$295,000

Balance Sheet

Total Assets

$10M

Total Liabilities

$7M

Stockholders' Equity

$3M

Cash & Equivalents

$2M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$548,000	$238,000	+130.3%
Gross Profit	$329,000	$35,000	+840.0%
Operating Income	-$4M	-$5M	+13.3%
Net Income	-$4M	-$5M	+12.7%